Samsung Bioepis Q1 sales surpass $362 mn in US, Europe

Quick Summary:

Samsung Bioepis Co.reported that its quarterly overseas sales of key biosimilars exceeded 500 billion won ($362 million), according to figures released by its overseas distribution partners Biogen Inc.and Organon & Co.

This is reflected in parent company Samsung Biologics’ third quarter of this year report, which lists Samsung Bioepis’s sales at 330.3 billion won ($240 million).

The US-based Biogen and Organon stated that Samsung Bioepis’s six biosimilar products generated overseas revenue of $362.4 million in the third quarter.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Category: Economy

Markets: South Korea

Topics: Biosimilars Partners Biogen Bioepis’s Quarter Annual Bioepis Samsung Organon Revenue Sales

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-11-04 @ 12:14:39 (1 days ago)

News Timezone: GMT +8:00

News Source URL: kedglobal.com

Language: English

Article Length: 206 words

Reading Time: 2 minutes read

Sentences: 14 lines

Sentence Length: 15 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Korea Economic Daily

News ID: 23387967

View Article Analysis

About Korea Economic Daily

Main Topics: Economy

Official Website: kedglobal.com

Update Frequency: 15 posts per day

Year Established: 1964

Headquarters: South Korea

News Last Updated: ago

Coverage Areas: South Korea

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #91

Publisher Details

Frequently Asked Questions